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Abstract Developedcountriesaresufferingfromanepidemic
rise in immunologic disorders, such as allergy-related diseases
andcertain autoimmunities. Severalstudies havedemonstrated
a negative association between helminth infections and
inflammatory diseases (eg, allergy), providing a strong case
for the involvement of helminth infections in this respect.
However, some studies point in the opposite direction. The
discrepancy may be explained by differences in frequency,
dose,time,andtypeofhelminth.Inthisreview,newstudiesare
discussed that may support the concept that chronic helminth
infections in particular—but not acute infections—are associ-
ated with the expression of regulatory networks necessary for
downmodulating allergic immune responses to harmless
antigens. Furthermore, different components of regulatory
networks are highlighted, such as the role of regulatory Tand
Bcells,modulationofdendriticcells,earlyinnatesignalsfrom
structural cells (eg, epithelial cells), and their individual
contributions to protection against allergic diseases. It is of
great interest to define and characterize specific helminth
molecules that have profound immunomodulatory capacities
as targets for therapeutic application in the treatment or
prophylaxis of allergic manifestations.
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Introduction
The human immune system has evolved to mount appro-
priate defensive responses to various dangerous pathogens
while tolerating or ignoring the innocent ones. The constant
presence of chronic helminth, microbial, and protozoan
infections and the daily risk of acquiring food-, water-, and
vector-borne infections is still present in developing
countries, whereas this was largely controlled in econom-
ically developed and Westernized countries during the 20th
century. In contrast, Westernized countries now face very
different problems: the epidemic rise in obesity, cardiovas-
cular diseases, metabolic disorders, and hyperinflammatory
diseases. As such, alarming increases have been observed
in childhood allergy (eg, rhinitis, atopic dermatitis, and
allergic and nonallergic asthma [1]), inflammatory bowel
diseases (eg, Crohn’s disease and ulcerative colitis), and
autoimmune disorders (eg, type 1 diabetes and multiple
sclerosis) [2]. It has been proposed that education of the
immune system by certain microbes and parasites can
prevent in part the development of inflammatory diseases
[3]. Reduced infections due to improved health care and
personal hygiene and decreased exposure to microorgan-
isms and their products in our immediate environment as a
result of urbanization may lead to insufficient stimulation of
the immune system. This would result in an altered
programming of the immune system and allow uncontrolled
expression of inflammatory molecules, thus explaining the
rise of inflammatory diseases in Westernized countries.
Indeed, a large body of epidemiologic data indicates that
some infectious agents tend to control inflammatory
diseases, in which parasitic worms form an important
group. In particular, the interplay between helminth
infections and allergic disorders has been studied in great
detail. In the current review, we focus on this interaction
and highlight the importance of the infection dynamics and
regulatory network. Helminth-induced mechanisms not
only regulate host immunity to the worms, resulting in a
mutually beneficial environment for survival of both
parasite and host, but may also control the development
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DOI 10.1007/s11882-009-0085-3of allergic diseases. Finally, we focus on the benefit of these
new insights for the development of novel future therapies.
Do Helminths Protect Against Allergic Disease?
Evidence from Population Studies
The number of studies on associations between allergic
disorders and parasitic infections is still growing. One
approach that is frequently used to determine the relation-
ship between helminths and allergy is to study general
parameters for allergic reactions, such as allergen skin prick
provocation tests and questionnaires (clinician assessed or
self-reported). However, this does not apply to all types/
aspects of allergic disease, as physician diagnosis is
required at least for (allergic or nonallergic) asthma,
eczema, or rhinitis in conjunction with clinical symptoms.
A systematic meta-analysis of published findings attempted
to compare a large number of studies related to intestinal
helminth infection and different aspects of allergic disease
[4]. However, sufficient conclusions could not always be
drawn because of the relatively few studies that addressed
physician-diagnosed clinical symptoms. As such, studies
involving intestinal helminth infections did not yield a
general consensus regarding protection against different
forms of allergic disease.
However, caution should be taken in not overinterpreting
the general conclusions because several crucial factors that
are likely to influence the relationship between helminth
and allergic disease need to be taken into account [5].
Timing
The time of first infection and duration of infection are
likely to be important; early and/or long-lasting (chronic)
infections are more efficient in downmodulating allergic
disease, whereas later infections and/or sporadic, transient
infections may enhance allergic clinical symptoms [6]. For
example, the effect of geohelminths on the suppression of
atopy is more important early in life and may cause a fixed
deviated immune phenotype that is not changed later in life,
after elimination of the infection [7]. Indeed, recent studies
show that maternal geohelminth infections could affect
infant immunity [8, 9], raising the possibility that the
immunologic effects of infection start in the fetus.
Intensity
Heavy parasite burden may induce immune suppression,
whereas mild infections may promote allergic disease. In
the meta-analysis, all published studies were included that
reported parasitic infection in at least 1% of the available
study population [4]. This led to an enormous variation in
helminth intensities and species of parasitic helminths. In
some endemic areas, close to 100% of the inhabitants may
be infected, representing intense and chronic helminth
infections, whereas in others, helminth infections can occur
occasionally and in a small percentage of the population,
with an intensity that is often mild. In areas with at least
moderate endemicity for different species of helminth
parasites, a considerable number of studies have demon-
strated an inverse association between helminth infections
and allergic disorders. For example, chronic infections with
intestinal helminths (Ascaris, Trichuris, and hookworms)
were reported to protect against allergic reactivity in
populations in Venezuela, Gambia, Ethiopia, Taiwan, and
Ecuador [10]. However, in areas endemic for other
helminthes (eg, schistosomes or filarial), the presence of
infections also seems to be associated with lower preva-
lences of allergies, as shown in studies in Gabon, Brazil,
and Indonesia [10]. Similarly, chronic and intense Schisto-
soma heamatobium infections in Ghana were negatively
correlated with the prevalence of atopic disease, whereas
mild infections were not [11, 12]. Population studies in
areas in which helminth infection intensities are low are
conducted only sporadically [13, 14]; nevertheless, these
low-intensity helminth infections seem to potentiate atopic
disorders. In addition, some of the travelers to endemic
areas who become infected with schistosomes develop
acute schistosomiasis and can suffer from fever, lung
eosinophilia, and pulmonary symptoms such as cough and
shortness of breath [10].
Host Genetics
The ability to induce specific host immune regulatory
mechanisms may be partially determined by host genetics.
Individuals who are genetically susceptible to atopic
disease may be more likely to develop allergic responses
to helminth and allergens and may be genetically more
resistant to infection [15]. On the other hand, people in
rural Africa seem to suffer less from allergies, whereas
people of African ancestry who live in affluent countries
have a higher prevalence and greater severity of allergic
symptoms than natives of these host countries, pointing to
the involvement of genetic control in allergic diseases [12].
Different Helminth Parasites
Meta-analyses showed that infections with Trichuris,
hookworm, or schistosomes were primarily negatively
associated with allergen skin test reactivity, whereas
hookworm infections were also associated with a reduced
prevalence of allergic asthma [4, 16]. Although the sample
size was too small for the meta-analysis, a similar
association was found for schistosome infections and
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studies, Ascaris lumbricoides infection was associated with
an increased prevalence of asthma, pointing toward the
importance of the species of helminths in the relationship
between allergies and helminths. In addition, helminth
species for which humans are not the definitive host, such
as Toxocara spp, and for which chronic infection cannot be
established [18, 19] also seem to potentiate atopic disorders
rather than protect against them.
Important lessons can be learned from intervention
studies: short-term application of antihelminth drugs
(<12 months) in Ecuador did not change the prevalence of
atopy or clinical signs of allergy (wheeze) compared with
the untreated group [20]. Deworming for 12 months in a
large cohort of Vietnamese schoolchildren resulted in
increased allergen sensitization, but not in clinical allergies
such as eczema, wheeze, or rhinitis. However, long-term
treatment for intestinal helminths (>22 months) in
Venezuelan or Gabonese children resulted in increased
allergen sensitization and skin prick test reactivity to
house dust mite [21–23], supporting a direct link between
chronic and intense helminth exposure and protection
from allergy. To gain a better understanding of early
immunologic influence and its interplay with genetic risk
factors, this needs to be further addressed in large birth
cohort intervention studies in helminth-endemic areas.
The Helminth Paradox
Helminths are master regulators of the host immune
response, effectively minimizing immune attacks meant to
expel the worms and thereby ensuring their survival in the
host for years and limiting host tissue damage. They
strongly induce polarized T-helper type 2 (Th2) responses,
elevated serum IgE titers, and eosinophil-rich inflammation
infiltrates in the tissue. However, despite this strong Th2
polarization, chronic infections do not induce clinical
symptoms of allergic disease. This presents a paradox;
however, further characterization of helminth-induced
immune responses shows a strong regulatory network that
is discussed in the context of disordered immunoregulation,
as explained below.
Immune Suppression
It is postulated that chronic helminth infections can protect
against allergic disease because of their profound suppres-
sion of the host immune system, leading to a general T-cell
hyporesponsiveness that is facilitated by the induction of a
regulatory network. Thus far, this network has been
described to include the activity of regulatory T (Treg)
and B cells and modulation of innate immune cells, such as
macrophages, dendritic cells (DCs), and local stromal cells,
resulting in an anti-inflammatory environment characterized
by increased levels of interleukin (IL)-10 and transforming
growth factor (TGF)-β [24]. This hyporesponsiveness is
not only directed toward parasite antigens but seems to
extend to bystander antigens, such as vaccine antigens or
other pathogens. For example, impaired Th1 responses
were reported to tetanus toxoid immunization [25]o r
against influenza virus in Schistosoma-o rOnchocerca-
infected patients [25, 26], and reduced immune responses to
Bacille Calmette-Guérin (BCG) vaccination and to the
cholera vaccine during intestinal helminth infection [27].
Several studies have described interactions between
helminths and malarial parasites. Although the findings on
malaria–parasite loads are controversial, data on malaria
pathology seem more uniform, showing that helminth
infection protects against renal failure and cerebral malaria
[28]. Furthermore, a recent study showed higher IL-10
responses to malaria antigens in children infected with S.
haematobium and/or different geohelminth species [29].
It is hypothesized that bystander immunoregulation by
helminth infection can also control allergen-specific in-
flammatory responses and thereby lead to lower prevalence
of allergies in helminth-infected individuals. However,
control of bystander T-cell responses may depend on
particular life cycle stages or the severity/intensity of an
infection. Animal models offer great opportunities to
dissect the interplay between pathogens such as helminths
and allergic diseases. Several studies have been reported
recently.
Lessons from Animal Models of Helminth–Allergy
Interaction
To study the causal relationship between helminth infec-
tions and the development of allergic diseases, several
groups have developed combined murine models of allergic
inflammation, acute asthma, atopic dermatitis, and several
different helminth species. For example, studies with rodent
nematodes (eg, Heligmosomoides polygyrus) have demon-
strated that infection leads to strongly reduced ovalbumin-
driven eosinophilic airway inflammation and immune
responses to food allergens, but not decreased symptoms
of atopic dermatitis [30–32]. In part of these studies, the
effect was dependent on Treg cells, whereas in others, it
was reversed by treatment with blocking IL-10 antibodies
[30, 33]. A similar inhibition of lung inflammation and
airway hyperresponsiveness was demonstrated by Ascaris
suum eggs, A. suum extract implants, or Ascaris worm
products (eg, PAS-1) in an IL-10–dependent manner [34,
35] and correspondingly by infections with Nippostrongy-
lus brasiliensis [36]o rSchistosoma mansoni [37–39]. In
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on the activity of IL-10 [36–38] or on the activity of
forkhead box P3 (FoxP3)
+ Treg cells [39].
However, a few studies showed no effect or a partial
effect on airway inflammation, whereas some even found
an exacerbation of allergic disease. For example, early
infections with helminths such as A. suum [40]o r
Toxocara canis [41] potentiated airway inflammation,
and infection with Trichinella spiralis increased anaphy-
laxis in mice [42]. The opposing effects of different
parasitic helminths in murine models may suggest varia-
tions in the immune modulating capacity of distinct
species. However, this paradox could also very well
reflect the difference between acute and chronic stages of
infection. Indeed, by exploring acute and chronic infec-
tions with S. mansoni, we have observed a clear dose-
dependent reduction in ovalbumin-specific eosinophilic
airway inflammation and airway hyperresponsiveness that
was mediated by IL-10 during chronic, but not acute,
infection [37].
All together, it seems that helminth infections at chronic
stages are associated with general immunosuppression,
which can have protective effects in different allergic
disease models. The exact mechanisms by which these
parasites dampen allergic responses are probably multiple.
The next challenge is to find out which part of the
regulatory network provides the strongest and most long-
lasting allergen-specific inhibitory response, including the
identification of the parasite antigens that are responsible
for inducing this.
How Helminths Modulate Immune Responses
It is clear from a wealth of literature that both the worms
and eggs of different helminths can modulate immune
responses by affecting different types of innate and
adaptive immune cells. Based on the evidence, a model
can be put forth to explain how helminths suppress the
host immune system and guarantee their own survival. In
recent years, a great deal of new information has become
available that explains the immune hyperresponsiveness
by a complete regulatory network in which different cell
types are involved. Next to polarized Th2 responses, the
development of regulatory T and B cells and immune
modulation of myeloid cells, such as DCs, or alterna-
tively activated macrophages and early innate signals
from epithelial cells seems to be an important element of
a chronic helminth infection and could harbor putative
targets that are important for inhibition of allergic
diseases. The role of alternatively activated macrophages
was recently discussed elsewhere [43]a n di sn o t
addressed further here.
Regulatory T and B Cells
Several studies have shown that Treg cell activity (both by
natural CD4
+CD25
+FoxP3
+ and adaptive CD4
+IL10
+ Tr1
cells) protects against allergic disease [44]. In contrast,
patients with mutations in the FOXP3 gene leading to a loss
in the natural Treg compartment show several immune-
mediated pathologies, including allergy, whereas the activ-
ity of allergen-specific Treg cells from asthmatic patients
seems to be impaired [45]. Importantly, successful allergen-
specific immunotherapy in humans—that which leads to a
reduction in allergic symptoms—is associated with the
emergence of IL-10–producing Treg cells. Simultaneously,
the B-cell compartment is affected, which is evident from
an increase in IgG4 and IgA responses and a simultaneous
decrease in IgE [46]. Central to helminth-induced immune
regulation of allergic responses in humans is the cytokine
IL-10, which may be produced by several different cell
types, including helminth-induced regulatory T cells [47]
and B cells [48], of which the Treg cells are clearly the
most studied players.
For example, in patients suffering from onchocerciasis,
antigen-specific IL-10 and/or TGF-β–secreting Treg cells
werefound[49, 50], whereas in patients infected with Brugia
malayi, increased expression of FoxP3 (specific transcription
factor of natural Treg cells) was demonstrated, as was the
involvement of regulatory molecules such as TGF-β and
cytotoxic T-lymphocyte antigen 4 [51]. Likewise,
schistosome-infected individuals in Kenya and Gabon had
higher CD4
+CD25
hi and CD4
+CD25
hiFoxP3 T-cell levels
compared with uninfected individuals [52]. Importantly,
CD4
+CD25
hiFoxP3 Treg cells have a clear immunologic
impact on host immunity, as in vitro removal of CD4
+FoxP3
T cells from peripheral blood mononuclear cells of either
geohelminth- or schistosome-infected schoolchildren restored
BCG-specific proliferation and interferon-γ production [53],
a phenomenon that was not observed in endemic controls.
In animal models, chronic nematode infection increased
the number of FoxP3
+ T cells [24], while in chronic
schistosome infections, some studies noted increases in
FoxP3
+ Tc e l l s[ 24], whereas others did not [54]. Neverthe-
less, the frequency of CD103 on Treg cells increased during
disease progression [54], suggesting that these cells become
more active during chronic schistosomiasis [55].
Elevated IL-10 has been reported in many human and
murine studies in the context of helminth infections, but the
source and role of IL-10 seem to vary in response to
different helminth species. In some experimental models,
the high IL-10 levels were attributed to adaptive Treg cells
[30, 31, 56, 57], whereas in others, IL-10 has been linked to
non-Treg populations [38, 54, 58]. By using IL-10–
deficient mice and by adoptive transfer of different cell
subsets, it was shown that both T-cell and non-T-cell-
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immune modulation [56, 58, 59]. One important alternative
source of IL-10 could be the B cell.
B cells possess a variety of immune functions, including
production of antibodies, presentation of antigens, and
production of cytokines. A large body of literature—in
particular on models of autoimmunity, but also on trans-
plantation and cancer—shows that IL-10-producing B cells
have great potential to regulate T-cell-mediated inflamma-
tory responses and therefore are named regulatory B cells
[60, 61]. For example, IL-10-producing regulatory B cells
were shown to downmodulate experimental autoimmune
encephalomyelitis, collagen-induced arthritis, and inflam-
matory bowel disease [60]. In addition, in models of
chronic parasitic inflammation, such as chronic schistoso-
miasis and filariasis, IL-10-producing B cells were reported
[37, 62, 63] and associated with reduced pathology and
modulation of T-cell responses [64, 65].
Thus far, most evidence comes from murine models and
needs to be confirmed in humans. Nevertheless, a few
studies have focused on B cells in human populations. For
example, helminth infection in multiple sclerosis patients
was associated with reduced disease activity; the B cells
from these patients displayed enhanced production of IL-
10, in particular a CD1d
hi subset that was correlated with in
vitro inhibition of T-cell proliferation [66]. Similarly, we
found increased circulating IL-10-producing CD1d
hi B cells
in S. haematobium-infected Gabonese patients.
Although the concept that regulatory B cells can dampen
allergic inflammation still needs to be established in
particular in humans, a small number of allergy studies in
murine models have already provided supportive evidence.
For example, B cells were responsible for the induction of
local inhalation tolerance by inducing Treg cells during
continuous allergen exposure [67]. In addition, transfer of
schistosome-induced, IL-10-producing B cells strongly
reduced inflammation in different models of allergic
inflammation [37, 38, 63]. Interestingly, in H. polygyrus-
infected, allergen-sensitized mice, mesenteric lymph node
CD23
hi B cells transferred protection against allergic
airway inflammation in an IL-10-independent manner
[68]. Future studies must dissect the role of the different
(regulatory) B-cell subsets in immune suppression and
protection against allergic disease.
Immune Modulation of Dendritic Cells by Helminth
Products
DCs residing in the mucosal lining of various peripheral
tissues are central to the generation and polarization of
adaptive immune responses. The main functions of DCs are
to patrol the environment for possible danger signals,
immediately activate local innate immune cells, and
subsequently initiate appropriate adaptive immune
responses in which the function and cytokine production
of lymphocytes are completely determined by instructions
from the DCs. DCs—but also other innate immune or
resident tissue cells—are ultimately equipped to recognize a
great variety of pathogen-associated molecular patterns
(PAMPs) or danger-associated molecular patterns by means
of various families of pattern-recognition receptors, of
which the families of the Toll-like receptors (TLRs),
NOD-like receptors, RIG-like receptors, and the C-type
lectin receptors (CLRs) are presently the best known. As a
consequence of ligation of different pattern-recognition
receptors, DCs will receive signals that are subsequently
translated into different sets of Th1-, Th2-, Th17- or Treg-
polarizing molecules [69].
Thus far, a few signature molecules of various helminths
have been identified that can modulate DCs to drive strong
Th2 or Treg cell responses, a hallmark of helminth
infections. The most prominent example is omega-1, a
glycoprotein derived from schistosome eggs that specifi-
cally primes DCs to drive polarized Th2 responses [70, 71].
Its target receptor or signaling route is currently unknown,
although it has been suggested that its ribonuclease activity
is involved in its capacity to condition Th2-priming DCs
[71]. Another clear example is ES-62, a secreted
phosphorylcholine-containing glycoprotein of the filarial
nematode Acanthocheilonema viteae, as it conditions DCs
to induce Th2 responses via activation of TLR4, as it is
primarily mediated by its phosphorylcholine moiety [72].
Also, lacto-N-fucopentaose III (LNFPIII)/Le
x, a glycocon-
jugate carrying a carbohydrate structure found in schisto-
somes, has been implicated in TLR4-dependent priming of
Th2 responses via DCs [73]. However, the significance of
this latter finding remains controversial, as schistosome-
soluble egg antigens (SEAs) harboring this same Le
x motif
have been shown not to bind to TLR4 [74, 75] and are quite
capable of modulating DCs for Th2 priming in the absence
of TLR signaling [76]. Ligation of TLR2 by helminth
molecules seems to be more important for the conditioning
of DCs to drive regulatory responses. Monoacetylated
phosphatidyl serine lipids from schistosomes specifically
instructed DCs to preferentially induce IL-10-producing
Treg in a TLR2-dependent fashion [77], and although less
potent, phosphatidylserine lipids derived from Ascaris
worms had a similar effect [75]. Likewise, a recent report
described the induction of Treg cells by Schistosoma
japonicum HSP60-derived, peptide-treated APC in a
TLR2-dependent manner [78]. Recent reports even cite a
clear link between Treg cells and TLR2, as TLR2-deficient
mice showed a reduced number of CD4
+CD25
+ Treg cells
and immunopathology during schistosomiasis that was
controlled by TLR2-primed Treg cells [79]. Interesting in
this respect is the observation that Treg cells can respond
Curr Allergy Asthma Rep (2010) 10:3–12 7directly to TLR2 ligands, such as Pam3Cys, but not to
ligands of other TLR receptors, and this augments Treg cell
proliferation [80, 81].
Apart from TLRs, a growing body of evidence indicates
that CLRs—recognizing sugar moieties—also play an impor-
tant role in the sensing of helminth glycans by DCs. The
glycoproteins from SEAs are recognized and internalized by
human DCs in a DC-SIGN (specific intercellular adhesion
molecule-3-grabbing nonintegrin)-, mannose receptor-, and
macrophage galactose-type lection-dependent manner [74,
82]. The binding of SEAs to DC-SIGN was found to be
dependent on sugar motifs Le
x and LDN-F, while chemical
modification of the glycans present in SEAs abolished the
Th2-driving capacity of SEAs [83]. This, together with the
observation that Le
x-containing LNFPIII favors Th2-biased
responses [84] strongly suggests that CLRs play a dominant
role in conditioning DCs for induction of Th2 responses by
schistosomal antigens. Moreover, antigens from T. canis
have been recognized by DC-SIGN expressed on DCs [85],
whereas the induction of a Th2 response in vivo by antigens
of the parasitic nematode B. malayi as well as the free-living
nematode Caenorhabditis elegans was found to be depen-
dent on intact glycans [86]. This suggests that Th2 biasing
by helminth glycans is a general phenomenon and that
helminth glycans may serve as a conserved molecular pattern
that instructs DCs via CLRs to drive Th2-polarized
responses.
Many helminth products show the inability to classically
activate DCs, as exemplified by a mixture of high molecular
weightcomponentsfromA. suum that reduced the expression
of major histocompatibility complex (MHC)-II, CD80,
CD86, and CD40 molecules on mouse CD11c
+ DC, leaving
the cells hampered to support strong T-cell proliferative
responses in vitro. The inhibitory effect was abolished in IL-
10-deficient mice [87]. Similarly, SEAs also lack the
capacity to classically activate DCs [88]. As such, the
concept has been put forth that helminth products actually
potently suppress TLR-mediated DC activation by other
microbial PAMPs. This was confirmed by many studies
showingtheinhibitoryeffectsofhelminth-derivedcomponents
on TLR-induced activation as determined by inhibition of
proinflammatory cytokine production and expression of
MHC-II/costimulatory molecules [89]. The pathways under-
lying this suppression are still poorly understood. Interesting-
ly, the suppression of TLR-mediated responses by helminth
antigens has striking similarities to the effects induced by
several microbial pathogens that target DC-SIGN [90].
Overall there is a consistent picture that helminth
products, regardless of whether they interact with TLRs or
CLRs, fail to induce conventional DC maturation [91] and
inhibit DC activation induced by proinflammatory PAMPs,
which could impair Th1 development and bias the immune
response toward Th2 or regulatory responses.
Early Innate Signals from Neighboring Cells
Recent studies in mice with repeated airway delivery of
native allergens or respiratory viruses have highlighted the
critical role of innate signaling in the generation of allergic
pulmonary inflammation, which shows that the complex
immunologic response not only includes Th2 cell-driven
inflammation, but also the participation of Th1, Th2, Th17,
natural killer T cells, and airway epithelial cells (ECs). ECs
in particular can influence the functions of local immune
cells via the expression of a wide range of molecules,
including MHC-I and MHC-II, costimulatory molecules,
chemokines, cytokines, and prostaglandins. During the past
few years, a particular interest has been growing in three
novel EC-derived cytokines, thymic stromal lymphopoietin
(TSLP), IL-25, and IL-33, and their ability to influence
innate and adaptive immunity associated with Th2
cytokine-mediated inflammation at mucosal sites [92, 93].
TSLP affects DCs, T cells, natural killer T cells, and mast
cells. IL-25 primarily influences macrophages, Th2 cells,
eosinophils, and mast cells. IL-33 acts on T cells, mast
cells, eosinophils, and basophils, illustrating the broad role
of these cytokines in the regulation of inflammatory/allergic
processes [93]. However, these cytokines seem to have dual
functions, as they are involved in the development of
protective Th2 cytokine responses in the context of
helminth infections and strongly promote pathologic
responses in cases of allergic inflammation [94]. In view
of the hypothesis that certain helminth infections may
protect against allergic diseases, it seems contradictory that
helminths also induce these strong allergic inflammation-
inducing cytokines. However, the location and timing may
be important factors. For example, TSLP expression in the
skin and lung has been linked to pathologic Th2 cytokine-
mediated responses, whereas TSLP expression in the
intestine seems to play an important role in host protective
immunity, as TSLPR-deficient mice challenged with Tri-
churis failed to clear worms after infection [95]. However,
TSLP does not seem to be essential to every intestinal
helminth because the development of protective Th2
immune responses after infection with H. polygyrus and
N. brasiliensis was still intact in TSLPR
−/− mice [96].
Similarly, using the same knockout mice, it was found that
TSLPR signaling played only a minor role in the
development of Th2-dependent pathology in the lung, liver,
and intestine against S. mansoni eggs [97]. Collectively,
these findings suggest that although TSLPR signaling
serves a key role in allergen-driven Th2 responses, it exerts
only restricted regulatory activity during certain chronic
helminth infections. Similar to TSLP, IL-25 is required for
the development of a Th2 cytokine-mediated response and
protective immunity following Trichuris or Nippostrongy-
lus infection, as IL-25-deficient mice could not clear the
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stage, it is unclear whether IL-25 is induced only at the
beginning—during the acute phase of infection—and
how its activity is influenced by the immunoregulatory
processes that take place during chronic and severe
helminth infections. Little is known about IL-33 induc-
tion by helminths; thus far, its presence has only been
described following infection with Trichuris,i nw h i c h
the expression peaked early during infection, indicating
that IL-33 acts primarily during the initiation of these
responses [100]. More studies must be carried out to
evaluate the role of IL-33 in helminth infection, although
initial studies favor a model in which IL-33 is induced
early during infection and not so much during chronic—
allergy-protective—stages.
In helminth-infected or nonallergic, healthy individuals,
T cells remain nonresponsive to harmless allergens, likely
by actively created mucosal tolerance. New concepts are
being introduced that suggest that mucosal tolerance to
allergens may result from “tolerant” cross-talk between
lung ECs and mucosal DCs. In this respect, lessons can be
learned from the gut, in which intestinal ECs were found to
drive the differentiation of Treg-promoting DCs via the
expression of TGF-β and retinoic acid [101]. Likewise, a
similar role in homeostasis is suggested for lung ECs via
promotion of anti-inflammatory and prophagocytic cells
(eg, primary bronchial ECs induced macrophage differen-
tiation from monocytes [102], whereas a lung epithelial cell
line inhibited IL-12 and tumor necrosis factor-α production
from antigen-presenting cells) [103]. Tolerance induction in
the gut is strongly dependent on steady-state recognition of
normal microbiota, as demonstrated in germ-free or
knockout mice for specific TLRs, which recognize con-
served microbial motifs [104]. Interestingly, molecules
from several microorganisms could also induce IL-10
production in lung epithelial cell lines [105, 106]. These
recent findings point toward a novel and exciting concept
that microbial organisms can influence tolerance under
homeostatic conditions by influencing cross-talk between
ECs and other immune cells and pose the question of in
which respect helminth species could interfere in the cross-
talk of ECs and other immune cells.
Therapeutic Application
The case is now building that the epidemic rise in immuno-
logicdisordersinWesternizedcountries—forallergicdiseases
in particular—can be explained by a dysfunctional immune
regulation resulting from decreased parasitic infections (eg,
helminth infections). The question remains as to how this
newly gained insight can help to stop the allergic March or to
treat patients once they have become allergic. In search of
novel therapies, it would be ideal to exploit the ability of
chronic helminth infections to modulate the immune system.
Promising results have been obtained by treating colitis
patients with Trichuris suis, a whipworm that naturally
infects pigs, and worm-based therapies are under develop-
ment at several pharmaceutical companies [2]. Nevertheless,
it would be more practical to focus on individual
helminth-derived immunomodulatory molecules to selec-
tively induce regulatory immune responses and avoid any
possible side effects of natural worm infections. Some
laboratories are isolating agents from helminths that could
prove useful as therapeutic agents. These immunomodula-
tory parasite-derived compounds (detailed above) would form
an ideal basis for therapeutic application in the treatment of
hyperinflammatory disorders. However, one caveat in this
immunoregulatory scenario is the possible interference with
essentialresponsestootherantigens,suchasthosecontainedin
vaccinations, or to life-threatening pathogens. Therefore,
serious efforts should be made to generate antigen-specific
immunoregulation in order to circumvent dangerous side
effects.
Conclusions
There is evidence that chronic, but not acute, helminth
infection is driving responses that protect against allergic
disorders. It is hypothesized that particularly during the
course of chronic diseases, immunoregulatory processes are
switched on (eg, the development of regulatory T and B
cells, possibly via their priming by DCs, or innate signals
from epithelial cells that have been in contact with certain
signature immunomodulatory molecules). In view of these
conclusions, it would make sense to focus on molecules
that are expressed during the chronic phase of infection. A
few molecules have been identified (detailed previously)
that would make suitable candidates for therapy. It is
important that efforts be made to bring these molecules to
the clinic, preferably coupled to allergens to target allergen-
specific changes and allow low concentrations to be
effective.
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